Instrument Inactif

Communiqués Urovant Sciences Ltd.

Actions

UROV

BMG9381B1081

Recherche biotechnologique et médicale

Communiqués

13/04/22	Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 2022 American Urological Association Annual Meeting	BU
07/03/22	Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902	BU
20/12/21	Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® (vibegron) 75 mg	BU
08/11/21	Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients	BU
29/03/21	UROVANT SCIENCES LTD. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
12/02/21	Urovant Sciences : Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results	BU
11/02/21	Urovant Sciences : Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data and Safety Monitoring Board	BU
23/12/20	Urovant Sciences : Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)	BU
03/12/20	UROVANT SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Urovant Sciences - UROV	BU
24/11/20	Urovant Sciences : Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary Endpoint	BU
19/11/20	Urovant Sciences : Announces Positive Clinical Efficacy and Safety Data from Vibegron EMPOWUR Long Term Extension Study	BU
18/11/20	Urovant Sciences : RM LAW Announces Investigation of Urovant Sciences Ltd.	PR
18/11/20	UROVANT SCIENCES INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Urovant Sciences - UROV	BU
12/11/20	Urovant Sciences : Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding Shares	BU
12/11/20	Sumitovant Biopharma : and Urovant Sciences Announce Sumitovant's Acquisition of Remaining Stake in Urovant	PR
10/11/20	Urovant Sciences : to Present at the Jefferies Virtual London Healthcare Conference	BU
02/11/20	Urovant Sciences : Reports Second Quarter Fiscal Year 2020 Results	BU
27/10/20	Urovant Sciences : to Report Second Fiscal Quarter 2020 Financial Results	BU
07/10/20	Urovant Sciences : Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals	BU
08/09/20	Urovant Sciences : to Present at the H.C. Wainwright & Co. Annual Global Investment Conference	BU
13/08/20	Urovant Sciences : Reports Fiscal First Quarter 2020 Results	BU
06/08/20	Urovant Sciences : to Report First Fiscal Quarter 2020 Financial Results	BU
18/06/20	Urovant Sciences : Reports Fiscal Year and Fourth Quarter 2019 Results	BU
18/06/20	Urovant Sciences : Announces Collaboration with Sunovion Pharmaceuticals	BU
11/06/20	Urovant Sciences : to Report Fiscal Year and Fourth Quarter 2019 Results	BU